公开(公告)号：US20230143604A1

公开(公告)日：2023-05-11

申请号：US17914013

申请日：2021-03-25

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Antoine Charles Olivier HENNINOT ,  Derek Cecil COLE ,  Nicholas SCORAH

IPC: A61K38/26 ,  C07K14/605

CPC classification number: A61K38/26 ,  C07K14/605

Abstract: The present disclosure provides GIP receptor agonist peptide compounds suitable for once per week dosing (QW), said peptide compounds having an activating action on GIP receptors and use of the GIP receptor agonist peptide as a medicament for the treatment and/or prevention of emesis, or a symptom or condition associated with emesis. Specifically, a GIP receptor agonist peptide containing a sequence represented by any of the formulas (I)-(V) or a salt thereof, and a medicament comprising the same are provided.

公开(公告)号：US20220135638A1

公开(公告)日：2022-05-05

申请号：US17279266

申请日：2019-09-24

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Hiroshi IMOTO ,  Mari ADACHI ,  Yoko KANEMATSU ,  Taiji ASAMI ,  Ayumu NIIDA ,  Naoki NISHIZAWA ,  Derek Cecil COLE ,  Mack FLINSPACH ,  Nick SCORAH ,  Abhijit Suresh BHAT

IPC: C07K14/575 ,  A61K9/00 ,  A61K9/08 ,  A61K47/02 ,  A61K9/20 ,  A61P1/08

Abstract: The present disclosure provides GIP receptor agonist peptide compounds having an activating action on GIP receptors and use of the GIP receptor agonist peptide as a medicament for the treatment and/or prevention of diabetes, obesity, emesis, or a symptom or condition associated with diabetes, obesity, or emesis. Specifically, a GIP receptor agonist peptide containing a sequence represented by the formula (I) or a salt thereof, and a medicament comprising the same are provided. Formula I: P1-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12-A13-A14-A15-A16-A17-A18-A19-A20-A21-A22-A23-A24-A25-A26-A27-A28-A29-A30-A341-A32-A33-A34-A35-A36-A37-A38-A39-A40-A41-P2 (SEQ ID NO: 4), or a salt thereof, wherein each symbol is as defined herein, with the proviso that the GIP receptor agonist peptide does not have an amino acid sequence as provided in SEQ ID NOs: 4-569 disclosed in PCT/JP2018/013540.